去除初始T细胞预防慢性移植物抗宿主病
三项II期临床试验共纳入138例急性白血病患者,接受去除初始T细胞的PBSC移植,主要终点为慢性GVHD。3年慢性GVHD累积发生率7%,中度1%,重度0%;III级急性GVHD 4%,IV级0%;3年总生存77%。去除初始T细胞可降低严重急性和慢性GVHD,且未明显增加复发或非复发死亡风险。
要点
- 去除初始T细胞的PBSC移植后3年慢性GVHD累积发生率仅7%,重度为0%。
- III级急性GVHD发生率为4%,IV级为0%,II级急性GVHD为71%。
- 3年总生存77%,无慢性GVHD无复发生存68%,复发23%,非复发死亡8%。
核心结论
- 去除PBSC移植物中的初始T细胞可使严重急性GVHD和任何慢性GVHD的发生率极低,且未明显增加复发或非复发死亡风险,使这一新型移植物工程技术有别于其他造血细胞移植方法。
研究设计与样本
- 三项II期临床试验的累积数据分析,共纳入138例急性白血病患者,接受HLA相合亲缘或无关供者去除初始T细胞的PBSC移植,预处理含高剂量或中等剂量全身照射和化疗,GVHD预防采用他克莫司联合或不联合甲氨蝶呤或吗替麦考酚酯,受者接受CD34选择PBSC及去除初始T细胞的特定剂量记忆T细胞,中位随访4年。
主要发现
- 3年慢性GVHD累积发生率总计7%(95%CI 2至11),中度1%(95%CI 0至2),重度0%。
- III级和IV级急性GVHD分别发生于4%(95%CI 1至8)和0%,II级急性GVHD累积发生率为71%(95%CI 64至79),多为1期上消化道GVHD。
- 亲缘相合供者和无关相合供者移植受者的III级急性GVHD发生率分别为5%(95%CI 0至9)和4%(95%CI 0至9),慢性GVHD发生率分别为7%(95%CI 2至13)和6%(95%CI 0至12)。
- 3年总生存77%(95%CI 71至85),无慢性GVHD无复发生存68%(95%CI 61至76),复发23%(95%CI 16至30),非复发死亡8%(95%CI 3至13)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Graft-versus-host disease (GVHD) causes morbidity and mortality following allogeneic hematopoietic cell transplantation. Naive T cells (TN) cause severe GVHD in murine models. We evaluated chronic GVHD (cGVHD) and other outcomes in three phase II clinical trials of TN-depletion of peripheral blood stem-cell (PBSC) grafts. METHODS: One hundred thirty-eight patients with acute leukemia received TN-depleted PBSC from HLA-matched related or unrelated donors following conditioning with high- or intermediate-dose total-body irradiation and chemotherapy. GVHD prophylaxis was with tacrolimus, with or without methotrexate or mycophenolate mofetil. Subjects received CD34-selected PBSC and a defined dose of memory T cells depleted of TN. Median follow-up was 4 years. The primary outcome of the analysis of cumulative data from the three trials was cGVHD. RESULTS: cGVHD was very infrequent and mild (3-year cumulative incidence total, 7% [95% CI, 2 to 11]; moderate, 1% [95% CI, 0 to 2]; severe, 0%). Grade III and IV acute GVHD (aGVHD) occurred in 4% (95% CI, 1 to 8) and 0%, respectively. The cumulative incidence of grade II aGVHD, which was mostly stage 1 upper gastrointestinal GVHD, was 71% (95% CI, 64 to 79). Recipients of matched related donor and matched unrelated donor grafts had similar rates of grade III aGVHD (5% [95% CI, 0 to 9] and 4% [95% CI, 0 to 9]) and cGVHD (7% [95% CI, 2 to 13] and 6% [95% CI, 0 to 12]). Overall survival, cGVHD-free, relapse-free survival, relapse, and nonrelapse mortality were, respectively, 77% (95% CI, 71 to 85), 68% (95% CI, 61 to 76), 23% (95% CI, 16 to 30), and 8% (95% CI, 3 to 13) at 3 years. CONCLUSION: Depletion of TN from PBSC allografts results in very low incidences of severe acute and any cGVHD, without apparent excess risks of relapse or nonrelapse mortality, distinguishing this novel graft engineering strategy from other hematopoietic cell transplantation approaches.
引用
- Bleakley M, Sehgal A, Seropian S, et al. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. J Clin Oncol. 2022. PMID: 35007144. doi:10.1200/JCO.21.01755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。